Halozyme Therapeutics (HALO) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $107.00 -0.36%
Revenue Growth %: +36.2%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +36.2%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $56.9 million versus the consensus estimate of $67.8 million.
GUIDANCE:
Halozyme Therapeutics sees FY2019 revenue of $205-215 million, versus the consensus of $209.1 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
- Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
